Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Concord Medical Services Holdings's Debt-to-EBITDA or its related term are showing as below:
FRA:C2C'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -50.64 Med: -8.09 Max: 86.55
Current: -16.59
During the past 13 years, the highest Debt-to-EBITDA Ratio of Concord Medical Services Holdings was 86.55. The lowest was -50.64. And the median was -8.09.
FRA:C2C's Debt-to-EBITDA is ranked worse than 100% of 478
companies
in the Healthcare Providers & Services industry
Industry Median: 2.25
vs FRA:C2C: -16.59
Concord Medical Services Holdings (FRA:C2C) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Concord Medical Services Holdings Debt-to-EBITDA Related Terms
Concord Medical Services Holdings Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Concord Medical Services Holdings Debt-to-EBITDA Chart
FRA:C2C vs GBCS, ADIA, EHSI: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Concord Medical Services Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Concord Medical Services Holdings Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Concord Medical Services Holdings's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Concord Medical Services Holdings's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Concord Medical Services Holdings (FRA:C2C) has a Debt-to-EBITDA of -14.76 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Concord Medical Services Holdings. According to the industry distribution chart, Concord Medical Services Holdings ranks #999999 out of 478 companies in the Healthcare Providers & Services industry.
Is Concord Medical Services Holdings' Debt-to-EBITDA too high?
Concord Medical Services Holdings' current Debt-to-EBITDA is -14.76. Based on the distribution chart, Concord Medical Services Holdings ranks #999999 out of 478 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Concord Medical Services Holdings has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Concord Medical Services Holdings' Debt-to-EBITDA compare to GBCS and ADIA?
According to the Healthcare Providers & Services industry distribution chart, Concord Medical Services Holdings ranks #999999 out of 478 companies for Debt-to-EBITDA. This places Concord Medical Services Holdings in the lower half of its industry. The industry median Debt-to-EBITDA is 2.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.25, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Concord Medical Services Holdings. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Concord Medical Services Holdings's current Debt-to-EBITDA is -14.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Medical Services Holdings stock overvalued right now?
Concord Medical Services Holdings (FRA:C2C) has a current Debt-to-EBITDA of -14.76. The stock's GF Value™ is €10.01, compared to a current price of €6.25 — trading 37.6% below its estimated fair value. The current Debt-to-EBITDA is -14.76. Concord Medical Services Holdings' overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Concord Medical Services Holdings (FRA:C2C), the current Debt-to-EBITDA is -14.76 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Concord Medical Services Holdings (FRA:C2C) Overvalued in 2026?
Based on GuruFocus' analysis, Concord Medical Services Holdings stock appears to be undervalued.
The current stock price of €6.25 is trading 37.6% below its estimated GF Value™ of €10.01.
Key valuation signals for FRA:C2C:
Debt-to-EBITDA: -14.76
GF Value™: €10.01 vs. price of €6.25 (37.6% below fair value)
No single metric tells the full story. See the FRA:C2C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Concord Medical Services Holdings Business Description
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Geographically, the company derives revenue from PRC.
52GF Score
Get the complete analysis for FRA:C2C
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:C2C has been successfully added to your 
